Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study

Completed

Conditions studied: Breast Cancer, Cardiotoxicity

In brief

This is a companion study to the "Pragmatic Randomized Trial of Proton vs Photon Therapy for Patients with non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RadComp) Consortium Trial" (NCT02603341). The investigators will collect cardiovascular (CV) biomarkers and echocardiograms prior to, during, and for up to 1 year following radiation for a subset of patients enrolled on RadComp and to evaluate the impact of proton vs photon radiation therapy (RT) on CV function and structure.

Key facts

Study ID

NCT04361240

Run by

Abramson Cancer Center at Penn Medicine

People needed

172

Starts

2020-08-01

Expected to finish

2025-05-29

Last updated by the study team

2026-02-09

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Consented to RadComp
• Willing and able to provide written consent

You may not qualify if…

• Knowledge of randomization on RadComp prior to enrollment on companion study
• Non-diagnostic echocardiography windows as assessed on local read.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Northwestern Medicine — Warrenville, Illinois, United States
• Johns Hopkins — Baltimore, Maryland, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.